绿叶制药创新抗抑郁药LY03021获批临床试验
财中社11月11日电绿叶制药（02186）发布公告，宣布其1类创新药LY03021已获得中国国家药品监督管理局药品审评中心批准开展临床试验，旨在治疗抑郁症。LY03021是一种新型的抗抑郁药物，采用了针对去甲肾上腺素转运体（NET）、多巴胺转运体（DAT）和GABA A受体的三靶点作用机制，具有同类首创的潜质。
根据流行病学数据，我国抑郁症的终生患病率为3.4%，12个月患病率为2.1%。现有抗抑郁药物普遍存在起效慢、复发风险高等局限，LY03021通过增强GABA的激活、调节脑内谷氨酸与GABA的平衡，快速发挥抗抑郁作用。非临床研究显示，该药物在给药后24小时内显著改善抑郁症状，并具备良好的安全性，未观察到毒副作用剂量超出有效剂量50倍以上。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10